The Potential of VipAlbumin® to Chronic Inflammation in Type 2 Diabetes Mellitus Balb/C Mice Model
Dinia Rizqi Dwijayanti, M. Sasmito Djati, Mansur Ibrahim and Muhaimin Rifa’i
DOI : 10.3844/ajisp.2015.56.67
American Journal of Immunology
Volume 11, Issue 2
Diabetes Mellitus (DM) is one of diseases which have increasing number of sufferers every year. Almost all DM patients are type 2 DM. One of the causes of type 2 DM is a chronic inflammation due to an increase of circulating proinflammatory cytokines such as TNF-Î±, IFN-Î³ and IL-6. VipAlbuminÂ® from snakehead fish extract is expected to be useful as an alternative treatment of type 2 DM because of its proinflammatory activity. The aim of this study was to determine the effect of VipAlbuminÂ® on regulatory T cell activation, macrophage cells, proinflammatory cytokines and NF-ÎºB. The experiments were done by inducing mice model of type 2 DM with STZ 100 mg/kg BW and then gave them oral administration of VipAlbuminÂ® 0 mg/g BW, 0.01664 mg/g BW, 0.0416 mg/g BW and 10.4 mg/g BW for 14 days. The data were statistically analyzed with one way ANOVA with significance value 0.05% and Tukey test using SPSS version 16 for Windows. The results showed the decreasing number of regulatory T cells in type 2 DM mice, increasing number of macrophage cells and proinflammatory cytokines TNF-Î±, IFN-Î³ and IL-6 as well as the increasing number of NF-ÎºB as a transcription factor of inflammatory mediators in CD4+ T cells, CD8+ T cells and macrophages (CD68+) compared to healthy mice (pâ¤0.05). Oral administration of VipAlbuminÂ®for 14 days was proven to cure type 2 DM mice (K+) by increasing the number of regulatory T cells, decreasing the number of macrophage cells and proinflammatory cytokines TNF-Î±, IFN-Î³ and IL-6 and inhibiting NF-ÎºBin T lymphocytes CD4+, CD8+ and macrophages at the level equivalent to healthy mice and significantly different (p<0.05) compared with K+ group.
© 2015 Dinia Rizqi Dwijayanti, M. Sasmito Djati, Mansur Ibrahim and Muhaimin Rifa’i. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.